OSE Immunotherapeutics (OSE) - A change of pace with three new clinical trials

12:48 EDT 17 Apr 2019 | Edison Investment Research

Edison Investment Research - Pharmaceuticals & healthcare - OSE Immunotherapeutics : OSE has seen several positive developments in its pipeline over the past few months including the initiation of three new partnered clinical trials: a Phase I study with OSE-127 (Servier), a Phase I study with BI 765063 (previously OSE-172, Boehringer Ingelheim) and a Phase II study with Tedopi in pancreatic cancer (GERCOR). Two milestones were triggered totalling €19.5m, and an extra €7.5m is expected in H119 from BI. OSE also announced a new bispecific platform (pre-clinical), which it plans to feed with novel targets identified from a new collaboration with Léon Bérard Cancer Center. Our valuation is slightly higher at €190m or €12.8/share.
ISIN: FR0012127173

Original Article: OSE Immunotherapeutics (OSE) - A change of pace with three new clinical trials


More From BioPortfolio on "OSE Immunotherapeutics (OSE) - A change of pace with three new clinical trials"

Quick Search


Relevant Topics

BioPortfolio - life science, medical devices and pharmaceutical conference
BioPortfolio is a leading news, information and knowledge resource covering the global life science industries impacted on by biotechnology. The site aims to provide the lay person, the researcher and the management executive with a single location to so...

Health care (or healthcare) is the diagnosis, treatment, and prevention of disease, illness, injury, and other physical and mental impairments in humans. Health care is delivered by practitioners in medicine, chiropractic, dentistry, nursing, pharmacy, a...

Clinical Approvals
Clinical trials are a set of procedures in medical research conducted to allow safety (or more specifically, information about adverse drug reactions and adverse effects of other treatments) and efficacy data to be collected for health interventions (e.g...